Skip to content
Subscriber Only

Otsuka Can Block Generic Abilify as Court Rejects Appeal

The U.S. Supreme Court left intact a ruling that lets Otsuka Holdings Co.’s pharmaceutical unit block generic competition to its schizophrenia drug Abilify in the U.S. until April 2015.

The justices today turned away an appeal by Canadian generic-drug maker Apotex Corp. The company challenged the patent for Abilify’s active ingredient, contending it would have been obvious to scientists based on known research. A U.S. appeals court rejected that argument.